Paper2015395
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Berman E and 9 others. Blood, 1991. Cited by 372 papers, by iCite.
Cite this record
ConductScience Library. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Papers, record 2015395. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2015395
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Adult | |
| Analysis of Variance | |
| Cytarabine | |
| Daunorubicin | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Idarubicin | |
| Leukocyte Count | |
| Male | |
| Probability |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01822015 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Background |
Source ClinicalTrials.gov
Cited by73
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 372 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41012572 | Daunomycin Nanocarriers with High Therapeutic Payload for the Treatment of Childhood Leukemia. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41012572 | PubMed |
| 40853377 | Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients. | Ann Hematol | 2025 | https://conductscience.org/library/papers/40853377 | PubMed |
| 40235888 | Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. | World J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/40235888 | PubMed |
| 39936576 | Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. | Am J Hematol | 2025 | https://conductscience.org/library/papers/39936576 | PubMed |
| 39833882 | The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience. | BMC Pharmacol Toxicol | 2025 | https://conductscience.org/library/papers/39833882 | PubMed |
| 38493006 | Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy? | Blood Rev | 2024 | https://conductscience.org/library/papers/38493006 | PubMed |
| 37635400 | Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. | Am J Hematol | 2023 | https://conductscience.org/library/papers/37635400 | PubMed |
| 37434023 | Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study. | Invest New Drugs | 2023 | https://conductscience.org/library/papers/37434023 | PubMed |
| 36975206 | Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors. | Cancer Rep (Hoboken) | 2023 | https://conductscience.org/library/papers/36975206 | PubMed |
| 35680595 | [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | https://conductscience.org/library/papers/35680595 | PubMed |
| 35150326 | Blue light induces ROS mediated apoptosis and degradation of AML1-ETO oncoprotein in Kasumi-1 cells. | Med Oncol | 2022 | https://conductscience.org/library/papers/35150326 | PubMed |
| 34638721 | Cancer Therapy Challenge: It Is Time to Look in the "St. Patrick's Well" of the Nature. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34638721 | PubMed |
| 34320781 | Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? | Haematologica | 2021 | https://conductscience.org/library/papers/34320781 | PubMed |
| 30968179 | Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. | Cancer Chemother Pharmacol | 2019 | https://conductscience.org/library/papers/30968179 | PubMed |
| 30858954 | Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. | Mediterr J Hematol Infect Dis | 2019 | https://conductscience.org/library/papers/30858954 | PubMed |
| 30666113 | Idarubicin-loaded methoxy poly(ethylene glycol)-b-poly(l-lactide-co-glycolide) nanoparticles for enhancing cellular uptake and promoting antileukemia activity. | Int J Nanomedicine | 2019 | https://conductscience.org/library/papers/30666113 | PubMed |
| 29787320 | Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. | Expert Rev Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29787320 | PubMed |
| 29779333 | [Clinical observation of standard IA regimen as induction chemotherapy in 242 patients with newly diagnosed acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2018 | https://conductscience.org/library/papers/29779333 | PubMed |
| 29365393 | [Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients]. | Zhonghua Xue Ye Xue Za Zhi | 2017 | https://conductscience.org/library/papers/29365393 | PubMed |
| 28154969 | What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction? | Curr Treat Options Oncol | 2017 | https://conductscience.org/library/papers/28154969 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2015395
GET https://conductscience.org/api/papers/v1/2015395/cited_by?page=2